Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial [Phase 2]

View source ↗

Summary

Phase 2 trial updating safety and efficacy of Tislelizumab with Zanidatamab as second-line therapy in HER2-positive advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)
• Zanidatamab

Snippet

Sponsor: Yonsei University | Conditions: HER2-positive Gastric Cancer | Phase 2 | Status: UNKNOWN